细胞毒性T细胞
免疫系统
过继性细胞移植
T细胞
CD8型
细胞疗法
嵌合体(遗传学)
癌症研究
细胞生物学
效应器
癌症免疫疗法
乳酸乳球菌
免疫学
生物
免疫疗法
细胞
调节性T细胞
树突状细胞
肿瘤微环境
化学
免疫耐受
癌细胞
细胞因子
嵌合抗原受体
免疫检查点
抗原提呈细胞
医学
获得性免疫系统
CD28
作者
Jingwen Shen,Yanhong Chu,Yan Wang,Xinyi Chen,Yaohua Ke,Da Huo,Junmeng Zhu,Sen Hong,Sizhe Qin,Baorui Liu,Qin Liu
出处
期刊:中国科学通报:英文版
日期:2026-09-01
标识
DOI:10.1016/j.scib.2026.09.009
摘要
Adoptive cell transfer (ACT) has achieved durable clinical responses in hematological malignancies, yet remains limited in solid tumors owing to poor T cell infiltration, inadequate persistence, and tumor-driven immunosuppression. Here, we report a bio-orthogonally engineered probiotic-T cell chimera (T-FOLactis) that creates a mutually reinforcing cellular-microbial system, in which FOLactis, an engineered Lactococcus lactis expressing a Flt3L-OX40L fusion protein, provides localized immunostimulatory cues to enhance T cell activation and effector function, while adoptively transferred T cells serve as cytotoxic effectors and mobile carriers that facilitate delivery of the bacterial payload to the tumor microenvironment. Using strain-promoted azide - alkyne cycloaddition chemistry, FOLactis bacteria were covalently anchored onto the surface of T cells, generating a cell-bound platform for spatially restricted immune modulation. In syngeneic colorectal cancer models, T-FOLactis reduced tumor burden by 78.1% compared with saline-treated controls and by 65.0% relative to conventional ACT, while prolonging median survival from 22 to 46 d without overt systemic toxicity. Mechanistically, T-FOLactis promoted dendritic cell (DC) - T cell proximity and established a spatially organized immune-licensing niche that amplified the functional impact of FOLactis-induced inflammatory cues, including IL-18. This spatial configuration was associated with enhanced coupling of cytokine availability, DC maturation, local co-stimulation and cytotoxic CD8 + T cell effector programming. IL-18 blockade impaired this licensing program and reduced therapeutic benefit, supporting IL-18 as a key functional mediator within the DC-T cell licensing niche. Together, these findings establish a modular cell-surface engineering strategy for augmenting ACT in colorectal cancer through coordinated immune network engagement.
科研通智能强力驱动
Strongly Powered by AbleSci AI